PEP-CMV
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for PEP-CMV, covering 2025-07-09 to 2026-03-10. Get the full timeline:
Most recent: Clinical Trial Update: PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma [Phase 1, Phase 2]